The biotechnology industry in France plays a crucial role in healthcare and agriculture, focusing on the research and development of innovative treatments and solutions. Companies in this sector vary from startups to well-established firms, specializing in areas like drug discovery, immunotherapy, and regenerative medicine. France's robust investment in biotechnology, complemented by strong academic institutions and research facilities, drives advancements that improve patient outcomes and public health. As the demand for tailored healthcare solutions grows, the industry is likely to see increased collaboration and breakthroughs, particularly in addressing chronic diseases and pandemic preparedness.

This list features 21 biotechnology companies in France, varying in size from small teams to larger organizations. Headquartered across major cities like Paris and Toulouse, these companies were founded between 2005 and 2022, each carving a niche in areas such as immunotherapy, cell treatments, and natural compounds. With innovative technologies and a commitment to addressing critical health challenges, these firms contribute significantly to the biopharmaceutical landscape.

Read on to discover the top biotechnology companies thriving in France.

Top 21 Biotechnology Companies in France

1. Enterome

• Website: enterome.com
• Ownership type: Venture Capital
• Headquarters: Paris, Île-De-France, France
• Employee distribution: France 100%
• Latest funding: $3.2M, October 2023
• Founded year: 2011
• Headcount: 51-200
• LinkedIn: enterome

Enterome is a biotechnology firm based in Paris, France, founded in 2011. The company specializes in cancer immunotherapy and drug discovery, focusing on innovative therapies that target various cancers through its proprietary OncoMimics™ approach. Enterome's pipeline includes several promising candidates currently in clinical trials, such as EO2463 for non-Hodgkin lymphoma and EO2401 for glioblastoma. Their unique methodology leverages insights from the gut microbiome, aiming to generate effective immune responses against tumors. Enterome has recently secured funding, with a reported amount of approximately €3.18 million in October 2023, underscoring their active role in advancing cancer treatment options. The company collaborates with healthcare providers and researchers to bring new therapies to market, demonstrating a commitment to improving patient outcomes in oncology.

2. Inotrem

• Website: inotrem.com
• Ownership type: Venture Capital
• Headquarters: Paris, Île-De-France, France
• Employee distribution: France 97%, Belgium 3%
• Latest funding: November 2023
• Founded year: 2013
• Headcount: 11-50
• LinkedIn: inotrem-sa

Inotrem is a biotechnology company based in Paris, France, founded in 2013. The company specializes in immunotherapy aimed at controlling dysregulated inflammatory responses. Inotrem has developed nangibotide, a first-in-class TREM-1 inhibitor, which is currently in late-stage clinical trials for severe conditions such as septic shock and COVID-19. Their research extends to a broad monoclonal antibody program targeting chronic inflammatory diseases. Inotrem's approach is rooted in a deep understanding of the TREM-1 pathway, which plays a crucial role in inflammation. The company is committed to advancing precision medicine by developing both therapeutic and diagnostic tools to identify patients who would benefit most from their treatments. With a small but dedicated team, Inotrem is actively contributing to the biotechnology industry, focusing on innovative solutions for significant health challenges.

3. 4P-Pharma

• Website: 4p-pharma.com
• Ownership type: Private
• Headquarters: Lille, Hauts-De-France, France
• Employee distribution: France 100%
• Latest funding: $16.1M, April 2024
• Founded year: 2014
• Headcount: 11-50
• LinkedIn: 4p-pharma

4P-Pharma, established in 2014 and based in Lille, France, is a clinical-stage biotechnology company dedicated to addressing serious diseases that lack effective treatments. The company focuses on research and development, clinical trials, and drug development services, primarily targeting healthcare providers and patients. Their innovative business model emphasizes collaboration with academic institutions and strategic partnerships to accelerate the development of first-in-class therapies. 4P-Pharma has a robust pipeline that includes candidates for chronic and autoimmune diseases, respiratory infections, and ophthalmological conditions. Recently, they secured €15 million in funding, which will support their ongoing projects and enhance their operational capabilities. The company is committed to transforming scientific advancements into successful drug therapies, ensuring that patient needs remain at the forefront of their development process.

4. Xenothera

• Website: xenothera.com
• Ownership type: Venture Capital
• Headquarters: Nantes, Pays De La Loire, France
• Employee distribution: France 100%
• Latest funding: Other (Grant), $2.6M, June 2021
• Founded year: 2014
• Headcount: 11-50
• LinkedIn: xenothera

Xenothera, founded in 2014 and based in Nantes, France, is a biotechnology company dedicated to developing innovative treatments through glyco-humanized polyclonal antibodies. The company primarily targets unmet medical needs in oncology and infectious diseases, focusing on creating effective therapies that can improve patient outcomes. With a team of approximately 27 employees, Xenothera is actively involved in clinical trials, including their promising candidates XON7 and LIS1, which are aimed at treating various forms of cancer and supporting solid organ transplantation. The company has also made headlines with its anti-COVID antibody, XAV-19, which has shown clinical efficacy. In June 2021, Xenothera secured funding amounting to over 2.5 million euros, further enabling their research and development initiatives. Their commitment to rapid development and patient-centric solutions underscores their role in the biotechnology industry.

5. TreeFrog Therapeutics

• Website: treefrog.fr
• Ownership type: Private Equity
• Headquarters: Pessac, Nouvelle-Aquitaine, France
• Employee distribution: France 91%, United States (USA) 9%
• Latest funding: February 2025
• Founded year: 2018
• Headcount: 51-200
• LinkedIn: treefrog-therapeutics

TreeFrog Therapeutics, founded in 2018 and based in Pessac, Nouvelle-Aquitaine, France, is a biotechnology firm dedicated to advancing cell therapies and regenerative medicine. The company specializes in developing innovative treatments for serious conditions, including Parkinson's disease and liver diseases, utilizing its proprietary C-Stem™ technology. This technology enables the production of cell therapies at a commercial scale, with a focus on safety and efficacy. TreeFrog is actively working on a pipeline of therapies, with its lead program set to enter first-in-human trials by 2026. The company has raised a total of $82 million since its inception, which supports its ambitious research initiatives and partnerships aimed at expediting the delivery of therapies to patients. With a team of approximately 175 employees, TreeFrog is positioned at the forefront of biotechnology innovation, striving to make cell therapies accessible to a broader patient population.

6. Mabqi

• Website: mabqi.com
• Ownership type: Private
• Headquarters: Grabels, Occitanie, France
• Employee distribution: France 100%
• Latest funding: Other (Grant), $5.2M, February 2025
• Founded year: 2017
• Headcount: 11-50
• LinkedIn: imab-labs

Mabqi, founded in 2017 and based in Grabels, Occitanie, France, is a private biotechnology company that specializes in the development of innovative immunotherapy solutions and human antibodies. With a dedicated team of 26 employees, Mabqi focuses on providing advanced therapeutic products and services to pharmaceutical companies and research institutions. Their proprietary technology, which includes fully human synthetic phage display libraries, allows them to create unique therapeutic antibodies with applications in oncology and other areas. Mabqi's pipeline includes innovative therapeutic antibodies with pH-sensitive properties, adaptable to various pharmaceutical development formats such as ADC, TCE, and CAR-T. The company has also received funding, amounting to over 5 million euros, which supports their ongoing research and development efforts. Mabqi's commitment to scientific excellence is reflected in their collaborations and contributions to significant research publications, positioning them as a noteworthy entity in the biotechnology sector.

7. Theravectys

• Website: theravectys.com
• Ownership type: Corporate
• Headquarters: Paris, Île-De-France, France
• Employee distribution: France 100%
• Latest funding: $19.9M, February 2021
• Founded year: 2005
• Headcount: 11-50
• LinkedIn: theravectys

TheraVectys, founded in 2005 and based in Paris, France, is a biotechnology company dedicated to the development of innovative vaccines and immunotherapies for cancer and infectious diseases. The company specializes in lentiviral vector technology, which allows for the creation of effective therapeutic solutions. Theravectys has established a joint laboratory with the Institut Pasteur, enhancing its research capabilities and fostering collaboration in vaccine development. The company is currently advancing several vaccine candidates through clinical trials, including a promising therapeutic vaccine targeting HPV-induced cancers, which has recently received FDA clearance for Phase 1 trials. With a focus on addressing unmet medical needs, Theravectys aims to transform healthcare through its proprietary technology and strategic partnerships. In February 2021, the company secured approximately $20 million in funding to support its clinical trials and further research initiatives.

8. Hemarina

• Website: hemarina.com
• Ownership type: Venture Capital
• Headquarters: Morlaix, Brittany, France
• Employee distribution: France 100%
• Latest funding: Series C, March 2017
• Founded year: 2007
• Headcount: 11-50
• LinkedIn: hemarina

Hemarina, founded in 2007 and based in Morlaix, Brittany, France, is a biopharmaceutical company that specializes in developing health products derived from the hemoglobin of marine worms, specifically _Arenicola marina_. The company has created innovative solutions like HEMO2life®, which is designed for organ preservation, and HEMOXYCarrier®, a universal oxygen transport system. These products aim to address critical medical needs, particularly in the fields of transfusion medicine and organ transplantation. Hemarina operates its own aquaculture farm dedicated to the sustainable production of marine worms, ensuring a reliable source of its key raw material. The company has received recognition for its innovative approach, including awards such as the Prix Galien for medical devices. Hemarina's commitment to research and development, along with its collaborations with academic and clinical partners, positions it as a relevant player in the biotechnology industry.

9. Twb

• Website: toulouse-white-biotechnology.com
• Ownership type: Private
• Headquarters: Toulouse, Occitanie, France
• Employee distribution: France 100%
• Latest funding: $8.2M, January 2019
• Founded year: 2012
• Headcount: 51-200
• LinkedIn: toulouse-white-biotechnology-twb-

Toulouse White Biotechnology (TWB) is a private biotechnology company based in Toulouse, France, founded in 2012. With a workforce of around 70 employees, TWB specializes in industrial biotechnology, focusing on research and development aimed at sustainable production methods. The company plays a crucial role in facilitating collaboration between public research entities and industrial partners, driving innovation in biotechnological solutions. TWB offers a range of services, including project management for collaborative research and development, technical support, and assistance for start-ups. Their projects often involve the use of renewable resources to create valuable products, addressing the growing demand for eco-friendly industrial practices. In 2019, TWB secured funding of €8.25 million, which underscores its active role in the biotechnology sector and its potential for growth and impact.

10. Generare

• Website: generare.bio
• Ownership type: Venture Capital
• Headquarters: Paris, Île-De-France, France
• Employee distribution: France 100%
• Latest funding: Seed, $5.5M, October 2024
• Founded year: 2022
• Headcount: 1-10
• LinkedIn: generare-bioscience

Generare is a biotechnology firm based in Paris, France, founded in 2022. The company specializes in the discovery of natural bioactive molecules, utilizing advanced cloning technology to identify new compounds that can lead to innovative medical treatments. Generare's primary clientele includes pharmaceutical companies and research organizations that are focused on tackling critical health challenges, particularly antibiotic resistance. With a commitment to societal and environmental betterment, Generare aims to unlock nature's potential by translating complex microbial DNA into scalable platforms for drug discovery. They have recently secured seed funding of approximately €5.5 million, which will likely support their ongoing research and development efforts. Generare's work is crucial in a time when the need for new antibiotics and therapies is more urgent than ever.

11. Abolis Biotechnologies

• Website: abolis.fr
• Ownership type: Venture Capital
• Headquarters: Évry-Courcouronnes, Île-De-France, France
• Employee distribution: France 100%
• Latest funding: $38.8M, September 2024
• Founded year: 2014
• Headcount: 51-200
• LinkedIn: abolis-biotechnologies

Abolis Biotechnologies, established in 2014 and based in Évry-Courcouronnes, France, is a biotechnology firm dedicated to developing innovative solutions that cater to various sectors, including food, healthcare, cosmetics, and specialty chemicals. The company specializes in biomanufacturing, leveraging the capabilities of microorganisms to create sustainable and tailored industrial solutions. Abolis focuses on addressing environmental challenges while enhancing product quality, making it a key player in the shift towards more sustainable industrial practices. Their clientele includes businesses looking to improve their processes through advanced biotechnological methods. Recently, Abolis secured funding of approximately €38 million in September 2024, underscoring its growth potential and relevance in the biotechnology sector.

12. Core Biogenesis

• Website: corebiogenesis.com
• Ownership type: Venture Capital
• Headquarters: Paris, Île-De-France, France
• Employee distribution: France 100%
• Latest funding: Series A, $10.5M, July 2022
• Founded year: 2020
• Headcount: 11-50
• LinkedIn: core-biogenesis

Core Biogenesis, founded in 2020 and based in Paris, France, is a biotechnology firm dedicated to producing recombinant proteins and growth factors. The company serves researchers and organizations in the life sciences and biopharma sectors, focusing on high-quality, animal-free products essential for stem cell research and regenerative medicine. Their manufacturing facility in Strasbourg employs plant-based systems, specifically using Camelina sativa, to produce these proteins, which enhances sustainability and reduces reliance on traditional animal-derived sources. Core Biogenesis has recently secured $10.5 million in Series A funding, which will support their growth and development in the biotechnology field. Their product offerings include various recombinant growth factors and cytokines, designed to improve bioavailability and stability for cell-based applications, making them a notable player in the biotechnology industry.

13. Astraveus

• Website: astraveus.com
• Ownership type: Venture Capital
• Headquarters: Issy-Les-Moulineaux, Île-De-France, France
• Employee distribution: France 100%
• Latest funding: Other (Debt), $7.4M, December 2024
• Founded year: 2016
• Headcount: 51-200
• LinkedIn: astraveus

Astraveus, founded in 2016 and based in Issy-Les-Moulineaux, France, is a biotechnology company dedicated to advancing cell and gene therapies. The company specializes in developing innovative solutions to improve the manufacturing processes of cell therapies. Their flagship product, the Lakhesys™ Benchtop Cell Factory, integrates hardware, software, and consumables to streamline the production of cell therapies, making them more accessible to patients. With a workforce of around 63 employees, primarily in research and development, Astraveus is committed to pushing the boundaries of biotechnological innovation. The company has secured significant funding, totaling over €30 million, which includes a recent debt funding round of approximately €7.36 million in December 2024. This financial backing supports their ongoing research and development efforts, positioning them well within the biotechnology sector.

14. Amolyt Pharma

• Website: amolytpharma.com
• Ownership type: Venture Capital
• Headquarters: Écully, Auvergne-Rhône-Alpes, France
• Employee distribution: France 90%, United States (USA) 10%
• Latest funding: $1.1B, March 2024
• Founded year: 2015
• Headcount: 11-50
• LinkedIn: amolytpharma

Amolyt Pharma is a biopharmaceutical company based in Écully, Auvergne-Rhône-Alpes, France, founded in 2015. The company specializes in the research and development of innovative medicines aimed at treating rare diseases, particularly those related to endocrine disorders. With a workforce of approximately 39 employees, Amolyt Pharma operates primarily in France, with a smaller presence in the United States. The company has garnered significant financial backing, securing $1.05 billion in funding as of March 2024, which underscores its potential for growth and development in the biotechnology sector. Amolyt Pharma's commitment to addressing the challenges faced by patients with rare diseases positions it as a relevant player in the biopharmaceutical industry.

15. Voisin Consulting Life Sciences (VCLS)

• Website: voisinconsulting.com
• Ownership type: Corporate
• Headquarters: Paris, Île-De-France, France
• Employee distribution: France 44%, United States (USA) 16%, India 13%, Other 26%
• Latest funding: July 2019
• Founded year: 1997
• Headcount: 201-500
• LinkedIn: voisin-consulting-life-sciences

Voisin Consulting Life Sciences (VCLS), founded in 1997 and based in Paris, France, is a consulting firm that specializes in providing regulatory and health economic solutions tailored for life sciences companies. With a workforce of approximately 224 employees, VCLS offers comprehensive support in regulatory strategy, clinical research, and market access. Their services are designed to assist biotech, pharmaceutical, and medical technology clients in navigating the intricate regulatory landscape, thereby expediting product development across various therapeutic areas. VCLS's expertise spans multiple stages of medical device and drug development, including preclinical, clinical, and post-market phases. They also focus on emerging biotech and established pharma, providing insights into orphan drug development, digital health technologies, and more. By engaging with regulators and payers, VCLS helps clients effectively communicate and position their innovative products in the market, ensuring compliance and successful market entry.

16. Affilogic

• Website: affilogic.com
• Ownership type: Private
• Headquarters: Nantes, Pays De La Loire, France
• Employee distribution: France 100%
• Founded year: 2010
• Headcount: 11-50
• LinkedIn: affilogic

Affilogic, founded in 2010 and based in Nantes, France, is a biotechnology company dedicated to the development of Nanofitins, a novel class of therapeutic proteins. These proteins are engineered for various medical applications, including cancer treatment and the oral delivery of biologics. Affilogic collaborates with pharmaceutical companies and research institutions to advance drug development and delivery solutions. Their innovative approach includes creating multispecific Nanofitins that target multiple pathways in cancer treatment, as well as developing oral delivery systems for biologics, which could enhance patient compliance and treatment efficacy. The company has also engaged in projects supported by significant funding, such as a grant from the Bill & Melinda Gates Foundation aimed at addressing global health challenges. Affilogic's commitment to research and development, along with its strategic partnerships, positions it as a relevant player in the biotechnology industry.

17. Domain Therapeutics

• Website: domaintherapeutics.com
• Ownership type: Private Equity
• Headquarters: Illkirch-Graffenstaden, Grand Est, France
• Employee distribution: France 89%, Canada 11%
• Latest funding: Other (Grant), $10.8M, January 2024
• Founded year: 2008
• Headcount: 51-200
• LinkedIn: domain-therapeutics

Domain Therapeutics is a biopharmaceutical company based in Illkirch-Graffenstaden, France, founded in 2008. The company specializes in developing innovative cancer immunotherapies that specifically target G Protein-Coupled Receptors (GPCRs). Their mission is to reverse immunosuppression in cancer patients, thereby enhancing the efficacy of existing treatments. Domain Therapeutics operates through research and development partnerships, collaborating with healthcare providers and pharmaceutical companies to bring effective therapies to the clinic. The company has a robust pipeline of assets, including several programs in various stages of development, such as the EP4 receptor antagonist (DT-9081) and the A2aR/A2bR antagonist (M1069). Recently, they secured funding amounting to over 10 million euros, which reflects their ongoing commitment to advancing cancer treatment solutions. With a team of experienced professionals and a focus on precision medicine, Domain Therapeutics is positioned to make significant contributions to the field of immuno-oncology.

18. Greentech

• Website: greentech.fr
• Ownership type: Private
• Headquarters: Saint-Beauzire, Auvergne-Rhône-Alpes, France
• Employee distribution: France 66%, India 8%, Germany 3%, Other 23%
• Founded year: 1992
• Headcount: 51-200
• LinkedIn: greentech_4

Greentech, founded in 1992 and based in Saint-Beauzire, France, is a private biotechnology and cosmetic company. With a workforce of around 416 employees, Greentech focuses on the development and manufacturing of natural actives and extracts tailored for the beauty and health sectors. Their product range serves various industries, including cosmetics, pharmaceuticals, and nutraceuticals, emphasizing innovative solutions that cater to the increasing demand for natural and sustainable products. Greentech's expertise extends to the use of micro-organisms and algae, showcasing their commitment to harnessing biotechnology for health and beauty applications. The company is also engaged in ongoing research and has made significant investments in areas like precision fermentation, further solidifying its role in the biotechnology field.

19. ImCheck Therapeutics

• Website: imchecktherapeutics.com
• Ownership type: Private Equity
• Headquarters: Marseille, Provence-Alpes-Côte D'Azur, France
• Employee distribution: France 95%, United States (USA) 5%
• Latest funding: Other (Grant), $22.4M, August 2024
• Founded year: 2015
• Headcount: 11-50
• LinkedIn: imcheck-therapeutics

ImCheck Therapeutics, founded in 2015 and based in Marseille, France, is a biotechnology company dedicated to the development of innovative immunotherapeutic antibodies aimed at treating cancer and infectious diseases. The company is currently advancing its clinical pipeline, which includes ICT01, a monoclonal antibody that activates γ9δ2 T cells, and ICT41, a pathogen-agnostic candidate. Both candidates are in various stages of clinical trials, reflecting the company's focus on addressing significant medical needs. ImCheck has recently gained attention for receiving FDA Fast Track designation for ICT01 in combination with other treatments for acute myeloid leukemia, indicating its potential to improve patient outcomes. Furthermore, the company secured EUR 20.18 million in funding from the French government as part of the France 2030 initiative, which aims to support innovative biomedicine development in France. This funding will help accelerate the progress of their drug candidates, showcasing their commitment to advancing healthcare solutions.

20. Argobio Studio

• Website: argobiostudio.com
• Ownership type: Venture Capital
• Headquarters: Paris, Île-De-France, France
• Employee distribution: France 83%, United Kingdom (UK) 17%
• Latest funding: Series A, $60.4M, March 2021
• Founded year: 2021
• Headcount: 1-10
• LinkedIn: argobio

Argobio Studio, based in Paris, France, is a biotech company founded in 2021 that specializes in transforming cutting-edge innovations into successful biotech ventures. The company focuses on developing therapeutics through translational research and provides operational support for early-stage projects. Argobio collaborates closely with biotech startups and research institutions to advance new therapies, particularly in areas with significant medical needs. They have raised over 60 million euros in funding to support their mission, which includes incubating projects that target neurological disorders, cancer, and other critical health issues. Their portfolio features companies like Temper Bio, which is working on chronic inflammatory disease treatments, and Crucible Therapeutics, which focuses on therapies for ALS and frontotemporal dementia. Argobio's team consists of experienced scientists and entrepreneurs who guide these projects from conception to Series A financing, ensuring a robust pipeline of innovative therapeutic solutions.

21. GTP Bioways - Olon Company

• Website: gtp-bioways.com
• Ownership type: Corporate
• Headquarters: Toulouse, Occitanie, France
• Employee distribution: France 96%, Other 4%
• Latest funding: July 2024
• Founded year: 2000
• Headcount: 51-200
• LinkedIn: gtp-technology

GTP Bioways - Olon Company, based in Toulouse, France, is a contract development and manufacturing organization (CDMO) that has been operational since 2000. The company specializes in the biopharmaceutical industry, offering a comprehensive range of services that include process development, GMP manufacturing, and analytical services tailored for innovative therapies. With a workforce of approximately 156 employees, GTP Bioways focuses on supporting biopharma clients in the development and manufacturing of complex biologics, such as monoclonal antibodies, recombinant proteins, and nanodrugs. Their facilities are equipped to handle both non-GMP and GMP manufacturing, ensuring that they can meet the varying needs of their clients throughout the clinical development process. GTP Bioways prides itself on a client-centric approach, emphasizing flexibility and responsiveness to the unique challenges faced by biotechnology firms. Their expertise in process development and commitment to quality positions them as a valuable partner in the biopharmaceutical landscape.

Biotechnology Insights: Key Companies in France

Company	Headquarter	Size	Founded	Ownership
Enterome	Paris, Île-De-France, France	51-200	2011	Venture Capital
Inotrem	Paris, Île-De-France, France	11-50	2013	Venture Capital
4P-Pharma	Lille, Hauts-De-France, France	11-50	2014	Private
Xenothera	Nantes, Pays De La Loire, France	11-50	2014	Venture Capital
TreeFrog Therapeutics	Pessac, Nouvelle-Aquitaine, France	51-200	2018	Private Equity
Mabqi	Grabels, Occitanie, France	11-50	2017	Private
Theravectys	Paris, Île-De-France, France	11-50	2005	Corporate
Hemarina	Morlaix, Brittany, France	11-50	2007	Venture Capital
Twb	Toulouse, Occitanie, France	51-200	2012	Private
Generare	Paris, Île-De-France, France	1-10	2022	Venture Capital
Abolis Biotechnologies	Évry-Courcouronnes, Île-De-France, France	51-200	2014	Venture Capital
Core Biogenesis	Paris, Île-De-France, France	11-50	2020	Venture Capital
Astraveus	Issy-Les-Moulineaux, Île-De-France, France	51-200	2016	Venture Capital
Amolyt Pharma	Écully, Auvergne-Rhône-Alpes, France	11-50	2015	Venture Capital
Voisin Consulting Life Sciences (VCLS)	Paris, Île-De-France, France	201-500	1997	Corporate
Affilogic	Nantes, Pays De La Loire, France	11-50	2010	Private
Domain Therapeutics	Illkirch-Graffenstaden, Grand Est, France	51-200	2008	Private Equity
Greentech	Saint-Beauzire, Auvergne-Rhône-Alpes, France	51-200	1992	Private
ImCheck Therapeutics	Marseille, Provence-Alpes-Côte D'Azur, France	11-50	2015	Private Equity
Argobio Studio	Paris, Île-De-France, France	1-10	2021	Venture Capital
GTP Bioways - Olon Company	Toulouse, Occitanie, France	51-200	2000	Corporate

Want to Find More Biotechnology Companies?

If you want to find more companies that develop therapies, explore drug discoveries, and innovate treatments you can do so with Inven. This list was built with Inven and there are hundreds of companies like these globally.

With Inven you'll also get to know the company's:

• Detailed Ownership: Who owns the company? Is it a public or private company? What is the ownership structure?
• Contact data: Who are the founders and CEO's? What are their emails and phone numbers?
• Financials: How do these companies perform financially? What are their revenues and profit margins?

...and a lot more!